BAYER AG |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28.64 EUR | +4.72% |
|
+4.59% | -14.96% |
| 10:56am | Bayer: Monsanto wins U.S. appeal | CF |
| 10:38am | BAYER AG : Jefferies gives a Neutral rating | ZD |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows:
- agrochemicals (48.8%): herbicides, fungicides, insecticides, etc.;
- pharmaceutical products (38%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.;
- OTC products and nutritional supplements (12.7%);
- other (0.5%).
Net sales are distributed geographically as follows: Germany (5.1%), Switzerland (1.2%), Europe-Middle East-Africa (23.2%), the United States (30.6%), North America (3.5%), China (7.6%), Asia-Pacific (10%), Brazil (10.4%) and Latin America (8.4%).
Sector
Pharmaceuticals
Calendar
14/05/2024
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
27.35
EUR
Average target price
36.9
EUR
Spread / Average Target
+34.94%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -14.96% | 28.7B | |
| +33.25% | 699B | |
| +25.40% | 571B | |
| -3.55% | 364B | |
| +18.16% | 326B | |
| +4.36% | 286B | |
| +14.83% | 236B | |
| +4.91% | 198B | |
| -10.10% | 194B | |
| -3.69% | 149B |
- Stock Market
- Equities
- BAYN Stock
- News Bayer AG
- Bayer : Reports 'Sustained Clinical Benefit' From New Studies on Vitrakvi Cancer Drug
